such as co-infection with HIV and anti-HHV8 antibody titers, are crucial in determining who develops Kaposi's sarcoma and who does not. Co-infection with HIV leads to an enormous increase in the incidence of Kaposi's sarcoma, and the effect of HIV appears to be independent of anti-HHV8 antibody levels (13) . For other virus-related cancers, persistent and active viral infection is often vital, and it is possible that HIV infection might encourage the persistence of what would otherwise have been a self-limiting new infection by HHV8 or lead to the reactivation of latent HHV8 infection. Other mechanisms, such as HIV-related immune dysregulation or the effect of its transactivation (Tat) protein (14) , may also be involved, but as yet there is little direct evidence to explain why co-infection with HIV greatly enhances the development of Kaposi's sarcoma.
That high anti-HHV8 antibody titer is strongly related to Kaposi's sarcoma risk (irrespective of co-infection with HIV) suggests that increased expression of viral genes, perhaps through HHV8 viremia, may be relevant. Intriguing similarities are emerging between the effect of HHV8 in Kaposi's sarcoma and the effect of the closely related human herpesvirus, the Epstein-Barr virus, in Burkitt's lymphoma (15) . In both situations, high antibody titer appears to be a key indicator of which infected individuals will go on to develop a tumor. Further exploration of these analogies may well hasten our understanding of the mechanisms of viral carcinogenesis in humans.
Over the last few years, HHV8 has been tentatively linked to a variety of conditions, other than Kaposi's sarcoma. Molecular studies have consistently found HHV8 in association with some unusual lymphoproliferative disorders, primary effusion lymphoma and Castleman's disease [reviewed in (3); (16) ]. However, apart from these extremely rare malignancies, epidemiologic evidence indicates that HHV8 infection has little or no effect on common cancer types or sites, including cancer of the prostate, multiple myeloma, leukemia, and Hodgkin's disease (13) . In addition, Rezza et al. (12) report that HHV8 infection does not lead to an increased risk of AIDS-defining diseases, other than Kaposi's sarcoma.
There are few instances in cancer research where our understanding of the pathogenesis of a human cancer has progressed as rapidly as it has for Kaposi's sarcoma. Jaffe and Pellett (2) attributed this success to "the benefits gained from the synergy between epidemiologic and laboratory science." New collaborative research on the natural history of HHV8 infection and on the pattern of antibody response to infection should continue to shed light on why only some people who have been infected by HHV8 go on to develop Kaposi's sarcoma. At the same time, new information is likely to emerge about the way that HHV8 is transmitted. Although HHV8 can be transmitted from mother to child, by sexual contact, and via blood products (17) (18) (19) , other, as yet unknown, modes of transmission are likely to predominate in Africa (13) . Indeed, it is not yet known whether HHV8 can be spread through water or by oral-fecal contact, as the results of some epidemiologic studies of people with Kaposi's sarcoma (20) (21) (22) have suggested. Ongoing collaboration between epidemiologists and laboratory scientists should ensure that the remarkably rapid advance in knowledge about HHV8 infection and Kaposi's sarcoma continues into the future.
